Electrocortical changes associated with minocycline treatment in fragile X syndrome

Abstract

Minocycline normalizes synaptic connections and behavior in the knockout mouse model of fragile X syndrome (FXS). Human-targeted treatment trials with minocycline have shown benefits in behavioral measures and parent reports. Event-related potentials (ERPs) may provide a sensitive method of monitoring treatment response and changes in coordinated brain activity. Measurement of electrocortical changes due to minocycline was done in a double-blind, placebo-controlled crossover treatment trial in children with FXS. Children with FXS (Mean_age 10.5 years) were randomized to minocycline or placebo treatment for 3 months then changed to the other treatment for 3 months. The minocycline dosage ranged from 25–100 mg daily, based on weight. Twelve individuals with FXS (eight male, four female) completed ERP studies using a passive auditory oddball paradigm. Current source density (CSD) and ERP analysis at baseline showed high-amplitude, long-latency components over temporal regions. After 3 months of treatment with minocycline, the temporal N1 and P2 amplitudes were significantly reduced compared with placebo. There was a significant amplitude increase of the central P2 component on minocycline. Electrocortical habituation to auditory stimuli improved with minocycline treatment. Our study demonstrated improvements of the ERP in children with FXS treated with minocycline, and the potential feasibility and sensitivity of ERPs as a cognitive biomarker in FXS treatment trials.

Keywords

Fragile X syndrome EEG ERP cortical parameters minocycline

Get full access to this article

View all access options for this article.

References

Bear

Huber

Warren

(2004) The mGluR theory of fragile X mental retardation. Trends Neurosci 27: 370–377.

Berry-Kravis

(2002) Epilepsy in fragile X syndrome. Dev Med Child Neurol 44: 724–728.

Bilousova

Dansie

Ngo

. (2009) Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 46: 94–102.

Castren

Paakkonen

Tarkka

. (2003) Augmentation of auditory N1 in children with fragile X syndrome. Brain Topogr 15: 165–171.

Chuang

Zhao

Bauchwitz

. (2005) Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J Neurosci 25: 8048–8055.

D’Hulst

Kooy

(2007) The GABAA receptor: A novel target for treatment of fragile X? Trends Neurosci 30: 425–431.

Duncan

Barry

Connolly

. (2009) Event-related potentials in clinical research: Guidelines for eliciting, recording, and quantifying mismatch negativity, P300, and N400. Clin Neurophysiol 120: 1883–1908.

Ferri

Del Gracco

Elia

. (1995) Somatosensory evoked potentials and hyperekplexia outcome. Neurophysiol Clin 25: 28–30.

Guy

(1976) Clinical Global Impression (CGI). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare.

10.

Hessl

Berry-Kravis

Cordeiro

. (2009) Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment. Am J Med Genet B Neuropsychiatr Genet 150B: 545–553.

11.

Irwin

Patel

Idupulapati

. (2001) Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: A quantitative examination. Am J Med Genet A 98: 161–167.

12.

Jacquemont

Curie

des Portes

. (2011) Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 3: 64ra61.

13.

Leigh

MJ ND

Winarni

Rivera

. (2012) A double blind, placebo controlled trial of minocycline in children with fragile X syndrome. In: Pediatric Academic Societies Annual Meeting. Boston, MA.

14.

Musumeci

Bosco

Calabrese

. (2000) Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 41: 19–23.

15.

Musumeci

Elia

Ferri

. (1994) Evoked spikes and giant somatosensory evoked potentials in a patient with fragile-X syndrome. Ital J Neurol Sci 15: 365–368.

16.

Musumeci

Hagerman

Ferri

. (1999) Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 40: 1092–1099.

17.

Naatanen

Kujala

Escera

. (2011) The mismatch negativity (MMN) – a unique window to disturbed central auditory processing in ageing and different clinical conditions. Clin Neurophysiol 123: 424–458.

18.

Paribello

Tao

Folino

. (2010) Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 10: 91.

19.

Perrin

Pernier

Bertrand

. (1989) Spherical splines for scalp potential and current density mapping. Electroencephalogr Clin Neurophysiol 72: 184–187.

20.

Picton

Bentin

Berg

. (2000) Guidelines for using human event-related potentials to study cognition: Recording standards and publication criteria. Psychophysiology 37: 127–152.

21.

Rojas

Benkers

Rogers

. (2001) Auditory evoked magnetic fields in adults with fragile X syndrome. Neuroreport 12: 2573–2576.

22.

Schneider

Hagerman

Hessl

(2009) Fragile X syndrome – from genes to cognition. Dev Disabil Res Rev 15: 333–342.

23.

Schneider

Leigh

Adams

. (2012) Differences in Cortical Hyperexcitability in Fragile X Syndrome. In: 13th international fragile X conference. Miami, FL, USA.

24.

Sutcliffe

Nelson

Zhang

. (1992) DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet 1: 397–400.

25.

Tenke

Kayser

(2012) Generator localization by current source density (CSD): Implications of volume conduction and field closure at intracranial and scalp resolutions. Clin Neurophysiol in press.

26.

Utari

Chonchaiya

Rivera

. (2010) Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil 115: 433–443.

27.

Van der Molen

Van

der

Molen

Ridderinkhof

. (2011a) Auditory and visual cortical activity during selective attention in fragile X syndrome: a cascade of processing deficiencies. Clin Neurophysiol 123: 720–729.

28.

Van der Molen

Van

der

Molen

Ridderinkhof

. (2011b) Auditory change detection in fragile X syndrome males: A brain potential study. Clin Neurophysiol 123: 1309–1318.

29.

Van der Molen

Van

der

Molen

Ridderinkhof

. (2012) Attentional set-shifting in fragile X syndrome. Brain Cogn 78: 206–217.

30.

Zhong

Chuang

Bianchi

. (2009) BC1 regulation of metabotropic glutamate receptor-mediated neuronal excitability. J Neurosci 29: 9977–9986.